Back
to BiopharmaceuticalGlossaries.com
You are
here > Biopharmaceutical
Glossary
Homepage/Search Index > Newest biopharmaceutical definitions 21st
century Drug discovery & development Map
Informatics map Technologies
map Biology & chemistry map
Finding guide to terms in these glossaries Site
Map accelerator
mass spectrometry: Mass spectrometry
adaptive
clinical trials: Clinical trials
Bayesian
clinical trials: Clinical trials
biological
chemistry: Chemistry (& biology)
biomarker
guidelines: Biomarkers
biomathematics
Algorithms
biomedical polymers: Biomaterials
biomolecular
screening: Assays & screening
cell
specific biomarkers: Biomarkers
cellular
dielectric spectroscopy CDS: Technologies
chaperome:
-Omes & -omics
Clinical
Trial Design Task Force: Clinical
Trials
combination
therapies: Drug Discovery
& Development
**comparative
effectiveness research: Research
comparative
systems biology: Genomic Manipulation
& Disruption
computational
physiology: Drug discovery
informatics
computational
sensing: Labels Signaling
& detection
**connectome:
-Omes & -omics
Copy
Number Polymorphisms CNPs: SNPs and
Genetic Variations
developability:
Drug discovery &
development
diffusion
tensor imaging: Molecular
imaging
disproportionate
drug metabolite: Drug safety,
Pharmacovigilance & toxicology
drug
metabolism: Pharmacogenomics
eSNPs
expression SNPs: SNPs and genetic
variations
evidence
based toxicology: Drug safety,
Pharmacovigilance & toxicology
exploratory
IND: Regulatory Affairs
expressomics:
-Omes & -omics
follow-on
drug: Drug discovery &
development
fragment
based drug discovery Assays and screening
genetic
susceptibility: Molecular
diagnostics -- genetic & genomic testing
GIS
Geographic Information Systems: Molecular
Medicine and Diagnostics
glycomimetics:
Glycosciences
green
chemistry: Chemistry & biology
GWAS
Genome Wide Association Sequencing: Genomic
informatics human
induced pluripotent stem cells hiPS: Stem cells
inflammasome:
-Omes & -omics
integrative
and organ systems pharmacology: Pharmacogenomics
** in
vitro adventitious assays: Assays
& screening
in
vitro diagnostic multivariate index assays IVDMIAs: Genetic
& genomic testing
integrative
biology: Pharmaceutical
biology
kidney
safety biomarkers: Biomarkers
label
free detection: Labels
Signaling & detection
lead
hopping: Assays
lipidomics:
'Omes & 'omics
mass
spectrometry" IUPAC Mass Spectrometry Standard
definitions of terms relating to mass spectrometry Provisional recommendations http://www.iupac.org/reports/provisional/abstract06/murray_prs.pdf
materials
chemistry: Chemistry & biology
medical
resequencing: Sequencing
mesoscopic
biology: Expression genes & proteins
metabolite:
Drug safety, Pharmacovigilance &
toxicology
microdosing
Pharmacogenomics
microtissues:
Cell biology
mitochondriomics:
-Omes & -omics
molecular
biosensors: Labels
Signaling & detection
molecular
crowding: Biomolecules
molecular
electronics: Nanoscience
& miniaturization
molecular
events: Cancer diagnostics,
genomics, prognostics & therapeutics
molecular
pharmacology Pharmacogenomics
mRNA
biomarkers: Biomarkers
nanolabels:
Labels Signaling &
detection
nanomedicine:
Nanoscience & miniaturization
nanotechnology
in the clinical laboratory setting: Molecular
Medicine
natural
competence: DNA
network
pharmacology: Pharmacogenomics
next
generation sequencing: Sequencing
niche
busters: Drug discovery &
development
-Omes
& -omics: Lots of new terms including
alleome, chromatinomics, chromosonics, cryobionomics,
embryogenomics, epitomics, fragonomics, lectinomics, mitogenomics, Nobonomics,
paleogenomics, RNome, RNomics, separomics, strainomics, transgenomics
oncolytic:
Cancer diagnostics, prognostics & therapeutics
patient
engagement: Molecular
Medicine
patient
navigation: Cancer diagnostics,
genomics, prognostics & therapeutics
pharmacokinetics:
Pharmacogenomics
pharmacological
biomarkers: Biomarkers
pharmacologically
active metabolite: Drug safety,
Pharmacovigilance & toxicology
Phase
II clinical trial design: Clinical
Trials
Phase
zero, Phase O: Drug approvals
physiologically
based pharmacodynamics:
Pharmacogenomics
pipeline
problem: Drug discovery
post-genomic
chemistry: Chemistry & biology
preclinical
safety biomarkers: Biomarkers
predictive
ADME: Drug safety & pharmacovigilance
predictive
biomarkers: Biomarkers
predictive
toxicology: Drug safety, toxicology &
pharmacovigilance
process
chemistry: Chemistry & biology
Proteomic
Standards Initiative: Proteomics
quantitative
pharmacology: Pharmacogenomics resourceome:
-Omes & -Omics
ridiculome:
-Omes & -Omics
safety
pharmacology: Drug Safety &
Pharmacovigilance
selection
biomarkers: Biomarkers
semantic
systems biology:
Genomic & Proteomic Manipulation &
Disruption including RNAi
seromics:
See under autoantibodies: Cancer
diagnostics & genomics
small
molecule biomarkers: Biomarkers
solubility:
Chemistry & biology
supramolecular
electronics: Nanoscience &
miniaturization
**synthetic
biology: Drug discovery
informatics
systems
pharmacology: Pharmacogenomics
scaffold
hopping: Chemistry
Sentinel Initiative: Drug safety, toxicology
& pharmacovigilance
soft
drug design: Molecular
modeling
target
hopping: Drug targets
therapeutic
antibodies: Drug targets
top-down
mass spectrometry: Mass spectrometry
translational
biomarkers: Biomarkers
translational
pharmacodynamics:
Pharmacogenomics
type
0, type I, type II biomarkers: Biomarkers
women's
health: Molecular Medicine
women's
health statistical modeling: Molecular
Medicine
Bibliography
Newest biopharmaceutical definitions
Evolving Terminologies for Emerging Technologies
Comments? Questions?
Revisions? Mary Chitty mchitty@healthtech.com
Last revised March 23, 2012
View
a Printer-Friendly Version of this Web Page!
<%end if%>
** newest of the new definitions
**health
disparities: Molecular
Medicine
**REMS Risk
Evaluation
and Mitigation Strategy : Drug Safety
Alpha
glossary index
How
to look for other unfamiliar terms